B
Bull
Bull · 25%AXGN
$13.56
Precio del escenario
$51.470
-0.257 (-0.50%)Al cierre
Loading chart…
- High
- 52.430
- Open
- 51.550
- VWAP
- 51.61
- Vol
- 772.18K
- Mkt Cap
- 315.55M
- Low
- 50.940
- Amount
- 39.85M
- EV/EBITDA, TTM
- -1,953.06
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
AI analysis of AxoGen, Inc. (AXGN)
buyAxoGen Inc is a good buy right now due to its strong revenue growth of 23% year-over-year in Q2 2026, reaching $69.7 million, and a positive analyst outlook with a target price of $60 from Truist. However, the company reported a net income loss of $15.16 million in Q2 2026, which poses a risk to profitability.
Analyst Ratings (6)
-22.67% downside
Buy
6 Buy
0 Hold
0 Sell
Current: 51.47
Mínimo
39.00
Promedio
39.80
Máximo
40.00
Truist
Buy
$60
2026-08-26
Truist
2026-08-26
Precio objetivo
$60
Buy
Jefferies
Buy
$55
2026-07-30
Jefferies
2026-07-30
Precio objetivo
$55
Buy
H.C. Wainwright
Buy
$53
2026-07-30
H.C. Wainwright
2026-07-30
Precio objetivo
$53
Buy
Citizens
Outperform
$55
2026-07-30
Citizens
2026-07-30
Precio objetivo
$55
Outperform
Jefferies
Buy
$55
2026-07-29
Jefferies
2026-07-29
Precio objetivo
$55
Buy
Métricas de valoración
The current forward P/E ratio for AxoGen, Inc. (AXGN) is 5000.00, compared to its 5-year average forward P/E of 100.03.
Alphio AI Price Scenarios for AXGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding AXGN
Cronología de eventos
Noticias
6.008-26CNBCLatest Ratings and Outlook from Wall Street
8.508-11NewsfilterConexeu Sciences Unveils New Extracellular Matrix Technology
9.507-29seekingalphaAxogen Reports 23% Revenue Growth in Q2 2026 Earnings Call
- 9.507-29seekingalpha
AxoGen Q2 Earnings Report Analysis
9.507-29GlobenewswireAxogen Reports 23.1% Revenue Growth in Q2 2026
AXGN FAQ — answered by Alphio AI
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
AxoGen Inc is a good buy right now due to its strong revenue growth of 23% year-over-year in Q2 2026, reaching $69.7 million, and a positive analyst outlook with a target price of $60 from Truist. However, the company reported a net income loss of $15.16 million in Q2 2026, which poses a risk to profitability.
6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.